What's new? Log in Free sign up

HUTCHMED (HCM)

Company Profile

Company profile

Ticker

HCM, HMDCF

Exchange

Website

www.hutch-med.com

CEO

Dr. Wei-Guo Su B.Sc., Ph.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Hutchison China MediTech Ltd

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

HCM stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Overseas Regulatory Announcement – Update on Transaction

HUTCHMED to Announce 2024 Final Results

Overseas Regulatory Announcement – Disposal Transaction

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Appointment of Cavendish as Joint Corporate Broker in London

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Capital International Investors

Capital International Investors

GENERAL ATLANTIC LLC

CK Hutchison Holdings Ltd

CK Hutchison Holdings Ltd

Capital International Investors

CK Hutchison Holdings Ltd

CK Hutchison Holdings Ltd

Financial summary

Financial statements Chart HCM financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from HUTCHMED earnings reports.

Institutional ownership, Q4 2024

HCM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	68	65	+4.6%
Opened positions	10	9	+11.1%
Closed positions	7	9	-22.2%
Increased positions	17	17	–
Reduced positions	24	20	+20.0%

13F shares	Current	Prev Q	Change
Total value	96.66 bn	134.99 bn	-28.4%
Total shares	339.32 mm	339.71 mm	-0.1%
Total puts	9.20 k	1.10 k	+736.4%
Total calls	8.20 k	6.20 k	+32.3%
Total put/call ratio	1.1	0.2	+532.4%

Largest owners	Shares	Value	Change
CK Hutchison	332.50 mm	$0.00	0.0%
Schroder Investment Management	2.77 mm	$39.76 bn	-5.3%
Allianz Asset Management GmbH	1.12 mm	$16.17 bn	-15.3%
UBS UBS	377.73 k	$5.44 bn	+264.5%
STT State Street	347.60 k	$5.01 bn	-0.5%
AAGIY AIA Group Limited	315.44 k	$4.55 bn	0.0%
M&G	265.79 k	$3.72 bn	-0.5%
Millennium Management	209.61 k	$3.02 bn	-32.4%
Renaissance Technologies	188.54 k	$2.72 bn	+18.4%
Amundi	170.25 k	$2.59 bn	-2.1%

Largest transactions	Shares	Bought/sold	Change
UBS UBS	377.73 k	+274.09 k	+264.5%
Allianz Asset Management GmbH	1.12 mm	-202.73 k	-15.3%
Schroder Investment Management	2.77 mm	-154.73 k	-5.3%
Acadian Asset Management	22.81 k	-145.90 k	-86.5%
Millennium Management	209.61 k	-100.37 k	-32.4%
MS Morgan Stanley	26.51 k	-70.28 k	-72.6%
D. E. Shaw & Co.	41.54 k	-51.73 k	-55.5%
XY Capital	46.68 k	+46.68 k	NEW
ABCCF Abc Arbitrage	34.71 k	+34.71 k	NEW
Jane Street	97.47 k	+34.47 k	+54.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Reported Earlier, HUTCHMED Secures Full NMPA Approval For ORPATHYS In China To Treat Advanced MET Exon 14 NSCLC

— Indication expands to include treatment-naïve patients —— The 2021 conditional approval in previously treated patients converted to full approval —

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025.

Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —Divestment proceeds to advance HUTCHMED's

Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer

Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance

Press releases

From Benzinga Pro

HUTCHMED to Announce 2024 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31,

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for the combination

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.